References
- Global Initiative for Asthma. The Global Initiative for Asthma (GINA) 2019). Available from: https://ginasthma.org/severeasthma/ [last accessed 3 November 20 2019].
- Kim H, Ellis AK, Fischer D, Noseworthy M, Olivenstein R, Chapman KR, Lee J. Asthma biomarkers in the age of biologics. Allergy Asthma Clin Immunol. 2017;13:48. doi:https://doi.org/10.1186/s13223-017-0219-4.
- Walter MJ, Holtzman MJ. A centennial history of research on asthma pathogenesis. Am J Respir Cell Mol Biol. 2005;32(6):483–489. doi:https://doi.org/10.1165/rcmb.F300.
- Gauthier M, Ray A, Wenzel SE. Evolving concepts of asthma. Am J Respir Crit Care Med. 2015;192(6):660–668. doi:https://doi.org/10.1164/rccm.201504-0763PP.
- Seys SF, Scheers H, Van den Brande P, Marijsse G, Dilissen E, Van Den Bergh A, Goeminne PC, Hellings PW, Ceuppens JL, Dupont LJ, et al. Cluster analysis of sputum cytokine-high profiles reveals diversity in T(h)2-high asthma patients. Respir Res. 2017;18(1):39. doi:https://doi.org/10.1186/s12931-017-0524-y.
- Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Arron JR, Koth LL, Fahy JV. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388–395. doi:https://doi.org/10.1164/rccm.200903-0392OC.
- Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088–1098. doi:https://doi.org/10.1056/NEJMoa1106469.
- Peters MC, Mekonnen ZK, Yuan S, Bhakta NR, Woodruff PG, Fahy JV. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 2014;133(2):388–394. doi:https://doi.org/10.1016/j.jaci.2013.07.036.
- Schleich F, Brusselle G, Louis R, Vandenplas O, Michils A, Pilette C, Peche R, Manise M, Joos G. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014;108(12):1723–1732. doi:https://doi.org/10.1016/j.rmed.2014.10.007.
- Fahy JV. Type 2 inflammation in asthma-present in most, absent in many. Nat Rev Immunol. 2015;15(1):57–65. doi:https://doi.org/10.1038/nri3786.
- Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet. 2015;386(9998):1086–1096. doi:https://doi.org/10.1016/S0140-6736(15)00157-9.
- Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50. doi:https://doi.org/10.1038/nrd4624.
- Spahn JD, Malka J, Szefler SJ. Current application of exhaled nitric oxide in clinical practice. J Allergy Clin Immunol. 2016;138(5):1296–1298. doi:https://doi.org/10.1016/j.jaci.2016.09.002.
- Saito J, Gibeon D, Macedo P, Menzies-Gow A, Bhavsar PK, Chung KF. Domiciliary diurnal variation of exhaled nitric oxide fraction for asthma control. Eur Respir J. 2014;43(2):474–484. doi:https://doi.org/10.1183/09031936.00048513.
- Tan BK, Chandra RK, Pollak J, Kato A, Conley DB, Peters AT, Grammer LC, Avila PC, Kern RC, Stewart WF, et al. Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;131(5):1350–1360. doi:https://doi.org/10.1016/j.jaci.2013.02.002.
- deShazo RD, Kemp SF. Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis. UpToDate. Available from: https://www.uptodate.com/contents/allergic-rhinitis-clinical-manifestations-epidemiology-and-diagnosis [last accessed 25 January 2018].
- Marcus P, Arnold RJG, Ekins S, Sacco P, Massanari M, Stanley Young S, Donohue J, Bukstein D, on behalf of the CHARIOT Study Investigators. A retrospective randomized study of asthma control in the US: results of the CHARIOT study. Curr Med Res Opin. 2008;24(12):3443–3452. doi:https://doi.org/10.1185/03007990802557880.
- Blakey JD, Price DB, Pizzichini E, Popov TA, Dimitrov BD, Postma DS, Josephs LK, Kaplan A, Papi A, Kerkhof M, et al. Identifying risk of future asthma attacks using UK medical record data: A respiratory effectiveness group initiative. J Allergy Clin Immunol Pract. 2017;5(4):1015–1024e8. doi:https://doi.org/10.1016/j.jaip.2016.11.007.
- Denlinger LC, Phillips BR, Ramratnam S, Ross K, Bhakta NR, Cardet JC, Castro M, Peters SP, Phipatanakul W, Aujla S, National Heart, Lung, and Blood Institute’s Severe Asthma Research Program-3 Investigators, et al. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med. 2017;195(3):302–313. doi:https://doi.org/10.1164/rccm.201602-0419OC.
- Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219–233. doi:https://doi.org/10.1007/s12016-018-8712-1.
- The ICC/ESOMAR Code. Available from: https://www.esomar.org/what-we-do/code-guidelines [last accessed 06 December 2019].
- Global Initiative for Asthma. The Global Initiative for Asthma (GINA) 2018). Global Strategy for Asthma Management and Prevention [last accessed 16 January 2020].
- Bouquet J, et al. Allergy. 2008;638–160.
- Ayelign B, Akalu Y, Teferi B, Molla M, Shibabaw T. Helminth induced immunoregulation and novel therapeutic avenue of allergy. J Asthma Allergy. 2020;13:439–451. doi:https://doi.org/10.2147/JAA.S273556.